<DOC>
	<DOCNO>NCT01591434</DOCNO>
	<brief_summary>Based upon in-vitro data AQUACEL® Extra™ achieve 39 % increase absorbency . As anticipated improved exudate management longer wear time achieve AQUACEL® Extra™ group compare AQUACEL® management chronic wound venous leg ulcer .</brief_summary>
	<brief_title>Study Evaluate Performance AQUACEL® Extra™ Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Subjects 18 year , willing able provide write informed consent . Subjects ankle brachial pressure index ( ABPI ) 0.8 great Subjects venous leg ulcer ( i.e . CEAP classification C6 1 ) duration le 24 month Subjects whose ulcer small 2cms one direction Subjects whose ulcer great 11cm one direction ( measure long length wide width ) Subjects ' whose index leg ulcer moderate heavy level exudate . Subjects whose index ( study ) leg currently treat compression therapy whose leg oedema control Subjects willing able comply requirement clinical investigation plan relation dressing/compression regime ability attend dress change require . Subjects history skin sensitivity component study dressing ( AQUACEL® Extra™ , AQUACEL® , &amp; DuoDERM™ Extra Thin ) Subjects whose wound consider clinically infected baseline Subjects whose leg ulcer malignant , recent deep venous thrombosis venous surgery within last 3 month . Subjects progressive neoplastic lesion treat radiotherapy chemotherapy , ongoing treatment immunosuppressive agent Subjects exhibit medical condition , accord Investigator , justify subject 's exclusion study Subjects participate clinical study within past month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>